PaxMedica, Inc. — Cyborg Score 3/10

Strategic Profile

The company was formerly known as Purinix Pharmaceuticals and rebranded to PaxMedica in April 2020. PaxMedica listed on NASDAQ in August 2022, pursuing specialized immunological and neurological drug development with a focus on rare and unmet medical needs in neurodevelopmental disorders.

Cyborg Score Rationale

The company has an extremely low market cap of approximately $12,563 with a stock price near historic lows of $0.0001. The company remains pre-revenue in development stages with significant capital requirements and regulatory risks inherent to clinical-stage biotech.

Top Insights

• PAX-101 targets multiple high-unmet-need indications including autism spectrum disorder and long COVID-19 syndrome
• Company currently trades on OTC Markets rather than NASDAQ despite earlier IPO listing
• Active research collaboration with PolarMar Health for Phase II trials in autism spectrum disorder
• Stock has declined substantially from historical highs, indicating significant challenges in capital markets perception

Named Competitors

• Sage Therapeutics — CNS-focused biopharmaceutical company
• Biohaven Pharmaceuticals — Rare neurological disorder treatment focus
• Akcea Therapeutics — Neurological and neuroinflammatory disease focus

Recent Developments

• (April 2024) Company responded to emergency request for IV Suramin with commitment to provide immediate access to PAX-101
• (August 2022) PaxMedica completed NASDAQ IPO listing 1.5 million shares
• (February 2021) Announced positive topline data from Phase 2 dose-ranging trial for PAX-101 in autism spectrum disorder

Open the full interactive PaxMedica, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.